Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 6.32B +61.9% |
| Revenue (ttm) | 217.17M +58.7% |
| Net Income | -207.84M |
| EPS | -3.14 |
| Shares Out | 68.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,899,119 |
| Open | 93.90 |
| Previous Close | 85.58 |
| Day's Range | 90.00 - 99.00 |
| 52-Week Range | 55.31 - 122.20 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 131.14 (+42.07%) |
| Earnings Date | May 5, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $131.14, which is an increase of 42.07% from the latest price.
News
Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw $60.1M in revenue, driven by BBS and a strong U.S. launch of IMCIVREE for acquired HO, with over 150 start forms and positive payer response. International expansion advanced with EU approval and Japan NDA filing, supporting a robust outlook for 2026.
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- F...
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pedi...
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp...
Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
IMCIVREE’s U.S. launch for acquired HO is underway, with expansion planned in Europe and Japan. Key pipeline updates include mid-year PWS data and phase III studies for new agents. The company is focused on rare MC4R pathway diseases, with strong cash reserves and a long-term vision for global leadership.
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra...
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceut...
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
PITTSBURGH, March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was se...
Rhythm Pharmaceuticals Transcript: Study update
IMCIVREE received FDA approval for acquired hypothalamic obesity, supported by phase III data showing significant BMI and hunger reductions. The launch targets a US population of about 10,000, with expanded sales and patient support teams, and ongoing efforts to secure broad payer coverage and international approvals.
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfun...
Rhythm Pharmaceuticals Transcript: Study result
The phase III EMANATE trial missed its primary endpoint in all four genetic obesity cohorts, but post-hoc analyses revealed significant BMI reductions in genetically confirmed POMC HET and SRC1 patients. High dropout rates and challenges in variant classification informed plans to focus future studies on next-generation MC4R agonists and improved patient selection.
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozy...
Rhythm Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing therapies for rare obesity disorders via the melanocortin-4 pathway, with a major HO launch pending FDA decision in March and global expansion underway. Next-gen therapies and robust IP aim to extend commercial life, while clinical data in Prader-Willi and genetic obesity support future growth.
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -...
Rhythm Pharmaceuticals Earnings Call Transcript: Q4 2025
IMCIVREE revenues grew 50% year-over-year to $194.8M in 2025, driven by U.S. and international expansion. Regulatory milestones for HO and new geographies are on track for 2026, with increased investment in R&D and commercial operations.
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic ob...
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market
RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), citing it as a commercial-stage biotech pioneering the rare genetic obesity market.
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
IMCIVREE is expanding into new indications, with strong clinical data in hypothalamic obesity and promising interim results in Prader-Willi syndrome. Sales growth is driven by BBS, and the company is preparing for a larger HO market with an expanded sales force and robust cash runway.
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preli...
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi s...
Rhythm Pharmaceuticals Transcript: Study Result
Preliminary phase II data in PWS show setmelanotide led to BMI reductions in most patients, with additional improvements in body composition and hyperphagia scores. The drug was well tolerated, and results support advancing to a phase III trial targeting a 5% placebo-adjusted BMI reduction.